Odyssean LLC Purchases 54,675 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Odyssean LLC boosted its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 81.1% during the 2nd quarter, HoldingsChannel reports. The fund owned 122,087 shares of the biopharmaceutical company’s stock after buying an additional 54,675 shares during the quarter. Ultragenyx Pharmaceutical makes up approximately 0.7% of Odyssean LLC’s investment portfolio, making the stock its biggest holding. Odyssean LLC’s holdings in Ultragenyx Pharmaceutical were worth $4,076,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $355,746,000. Vanguard Group Inc. raised its stake in Ultragenyx Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company’s stock worth $236,068,000 after acquiring an additional 131,087 shares in the last quarter. State Street Corp lifted its holdings in Ultragenyx Pharmaceutical by 16.5% during the 4th quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company’s stock valued at $98,970,000 after purchasing an additional 610,559 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Ultragenyx Pharmaceutical by 26.6% in the fourth quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company’s stock valued at $56,624,000 after acquiring an additional 516,781 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in Ultragenyx Pharmaceutical by 1,030.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company’s stock valued at $47,298,000 after purchasing an additional 2,057,951 shares during the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Wall Street Analyst Weigh In

RARE has been the topic of several research analyst reports. Wells Fargo & Company cut Ultragenyx Pharmaceutical from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $50.00 to $18.00 in a report on Thursday. The Goldman Sachs Group decreased their price objective on shares of Ultragenyx Pharmaceutical from $28.00 to $19.00 and set a “neutral” rating on the stock in a report on Friday. Evercore downgraded shares of Ultragenyx Pharmaceutical from an “outperform” rating to an “in-line” rating and set a $16.00 target price for the company. in a research note on Thursday. Citigroup reduced their target price on shares of Ultragenyx Pharmaceutical from $58.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $36.63.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Several analysts still see substantial potential upside after the selloff. Barclays maintained an “overweight” rating with a $32 price target, while Jefferies, Citigroup, TD Cowen, Canaccord Genuity, Cantor Fitzgerald and HC Wainwright retained bullish ratings despite sharply reducing their targets.
• Positive Sentiment: Ultragenyx is evaluating “significant” cost reductions following the trial failure, which could help preserve cash and improve the company’s financial outlook. Investors are also focusing on its existing commercial rare-disease portfolio. Ultragenyx to weigh significant cost cuts as Angelman drug fails key study
• Positive Sentiment: Unusually heavy call-option activity and speculation that Ultragenyx could become an acquisition target provide potential—but highly speculative—support for the stock. Ultragenyx potential M&A target
• Neutral Sentiment: Analyst views are increasingly divided. Goldman Sachs lowered its target to $19 and moved to “neutral,” while Barclays remains “overweight” at $32. Jefferies and Citi kept “buy” ratings but reduced targets to $28. The wide range reflects uncertainty over Ultragenyx’s post-trial growth prospects.
• Negative Sentiment: RBC downgraded the company to “hold,” while Bank of America, JPMorgan, Wells Fargo, Baird, Evercore, William Blair and others also reduced ratings or targets. Baird and Evercore now see only limited upside, signaling diminished confidence in the pipeline.
• Negative Sentiment: The Angelman syndrome failure creates greater dependence on Ultragenyx’s existing products and other pipeline programs. The company is weighing the future of the program, adding uncertainty around research spending, revenue growth and long-term valuation. Ultragenyx Angelman syndrome trial failure

Ultragenyx Pharmaceutical Trading Up 3.0%

Ultragenyx Pharmaceutical stock opened at $15.30 on Friday. The company has a market cap of $1.51 billion, a PE ratio of -2.62 and a beta of 0.31. Ultragenyx Pharmaceutical Inc. has a 1 year low of $13.81 and a 1 year high of $39.89. The company’s 50-day moving average is $27.76 and its two-hundred day moving average is $24.97.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The business had revenue of $214.00 million during the quarter, compared to the consensus estimate of $183.08 million. During the same period in the previous year, the firm posted ($1.17) earnings per share. Ultragenyx Pharmaceutical’s revenue for the quarter was up 28.5% compared to the same quarter last year. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -3.97 EPS for the current year.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, EVP Karah Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $24.62, for a total value of $46,753.38. Following the transaction, the executive vice president owned 94,462 shares of the company’s stock, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Corazon (Corsee) D. Sanders sold 2,000 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the transaction, the director owned 21,095 shares in the company, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their position. The disclosure for this sale is available in the SEC filing. 5.20% of the stock is owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.